A federal judge on Friday dismissed a lawsuit that challenged Colorado's power to cap prescription drug costs.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Long-standing trade agreements have largely sheltered the pharmaceutical industry from tariffs but President Donald Trump's ...

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

A federal judge has dismissed Amgen’s lawsuit against Colorado’s Prescription Drug Affordability Board, allowing the state to move forward with setting price ceilings on prescription drugs, The Denver ...

Already reeling from years of market chaos, the announced departure of CBER chief Peter Marks sent a ripple across biopharma ...

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization ...

LM Advisors LLC has injected $641,000 worth of confidence into Amgen, scooping up 2,460 shares in Q4. Several other firms ...

A federal judge threw out Amgen’s lawsuit against the state board empowered to set first-in-the-nation price ceilings on prescription drugs in Colorado, finding that the maker of arthritis medication ...

Shares of Amgen and IBM are posting strong returns Monday morning, sending the Dow Jones Industrial Average into positive territory.

In the case filed by Amgen last year, U.S. District Court Judge Nina Wang ruled that a Colorado state board can proceed with plans to limit the costs for medications. This is the first court decision ...